The nervous system relies on long nerve fibers called axons to transmit electrical signals between the brain, spinal cord, and body. In dogs affected by NAD-PLA2G6, the genetic mutation disrupts normal cellular maintenance processes, leading to degeneration of axons and gradual loss of neuronal function. This results in progressive neurological impairment as nerve signals become slower, weaker, or completely interrupted.
Clinical signs of NAD-PLA2G6 typically appear in young dogs, although onset and severity can vary depending on genetic background. Early symptoms may include mild coordination problems, stiffness, or subtle gait abnormalities. As the disease progresses, affected dogs often develop more pronounced neurological signs such as ataxia (loss of coordination), tremors, muscle weakness, and difficulty maintaining balance.
In more advanced stages, dogs may experience significant motor dysfunction, including difficulty walking, frequent falling, and reduced ability to control voluntary movements. Some dogs may also show behavioral changes, reduced activity levels, or signs of cognitive decline due to broader nervous system involvement. In severe cases, progressive neurological deterioration can significantly impact quality of life.
The NAD-PLA2G6 DNA Health Test is designed to detect the specific mutation in the PLA2G6 gene responsible for this condition. The test is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The collected DNA is analyzed in a specialized laboratory to determine whether the dog carries zero, one, or two copies of the mutation. Since DNA does not change throughout life, testing can be performed at any age, including before symptoms appear.
Results are generally reported in three categories:
- Clear (Normal): The dog does not carry the PLA2G6 mutation and is not expected to develop NAD or pass it to offspring.
- Carrier: The dog carries one copy of the mutation but typically does not show clinical signs. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and is likely to develop progressive neurological signs associated with NAD-PLA2G6.
Genetic testing for NAD-PLA2G6 is highly valuable for breeders, veterinarians, and dog owners. Breeders can use results to avoid producing affected puppies by preventing carrier-to-carrier matings, helping reduce the prevalence of this serious neurological disorder in breeding populations while maintaining genetic diversity.
For dog owners, knowing a dog’s genetic status allows for early monitoring and supportive care. While there is currently no cure for NAD-PLA2G6, supportive treatments such as physiotherapy, mobility assistance, and symptom management may help maintain comfort and quality of life. Regular veterinary neurological evaluations are important for tracking disease progression.
The Neuronal Axonal Deficiency (NAD-PLA2G6) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited axonal degeneration disorder in future generations.
